Voyager Therapeutics, Inc. (VYGR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Voyager Therapeutics, Inc. (VYGR) closed at USD 2.01 on 2026-10-14, a change of -56.9 % over the past year, with a market capitalization of USD 126.93M.

Voyager Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Voyager Therapeutics, Inc. key figures

Previous close

USD 2.01 (2026-10-14)

1-year change

-56.9 %

Market cap

USD 126.93M

Enterprise value

USD 43.16M

P/E ratio (trailing)

-1.20

P/E ratio (forward)

-1.61

EPS (trailing)

-1.72

EPS (forward)

-1.28

PEG ratio

n/a

Price to book

0.82

Revenue growth

-39.1 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.57

Employees

141

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Voyager Therapeutics, Inc. and compare it with other stocks.